Charles Quesada1, Benjamin Pommier2, Camille Fauchon3, Claire Bradley4, Christelle Créac'h5, François Vassal2, Roland Peyron5. 1. NEUROPAIN Team, Inserm U1028, Université Claude Bernard Lyon1 et Université Jean Monnet, Saint-Etienne, France; Centre Stéphanois de la Douleur, Hôpital Nord, Centre Hospitalier Régional Universitaire de Saint-Etienne, France. Electronic address: quesada.charles@gmail.com. 2. NEUROPAIN Team, Inserm U1028, Université Claude Bernard Lyon1 et Université Jean Monnet, Saint-Etienne, France; Service de Neurochirurgie, Hôpital Nord, Centre Hospitalier Régional Universitaire de Saint-Etienne, Australia. 3. NEUROPAIN Team, Inserm U1028, Université Claude Bernard Lyon1 et Université Jean Monnet, Saint-Etienne, France. 4. Queensland Brain Institute, The University of Queensland, Australia. 5. NEUROPAIN Team, Inserm U1028, Université Claude Bernard Lyon1 et Université Jean Monnet, Saint-Etienne, France; Centre Stéphanois de la Douleur, Hôpital Nord, Centre Hospitalier Régional Universitaire de Saint-Etienne, France; Service de Neurologie, Hôpital Nord, Centre Hospitalier Regional Universitaire de Saint-Etienne.
Abstract
OBJECTIVES: To confirm and extend previous results involving repetitive transcranial magnetic stimulation (rTMS) aimed at alleviating refractory central neuropathic pain (CNP). To evaluate pain relief in detail and to assess ongoing benefits after one year of treatment. DESIGN: Prospective observational study. SETTING: University hospital. Outpatient settings. PARTICIPANTS: Patients (N=80) with chronic central pain after brain or spinal cord injuries. INTERVENTIONS: High-frequency (20Hz) neuronavigated-rTMS sessions were applied on the primary motor cortex using a figure-of-eight coil positioned by a robotized arm. Patients received a minimum of 4 consecutive sessions, each separated by 3-4 weeks. MAIN OUTCOME MEASURES: Percentage of pain relief (%R), duration of pain relief (DPR), numeric rating scale (NRS), neuropathic pain symptom inventory (NPSI), and pain relief score (PRS). RESULTS: Seventy-one patients completed the study. On average, after the first 4 sessions, %R was 28% and DPR was 11 days. Fifty-four patients (76%) were responders with a permissive threshold of ≥10%R and 61% (43 patients) with a stringent threshold ≥30%R. After 12 months of treatment (15 sessions) we observed a cumulative effect on %R (48%), DPR (20d), and on the prevailing NPSI sub-score (-28%). This effect reached significance after 4 sessions and was further maintained over 12 months. Across participants, more than 1000 rTMS sessions were delivered over 6 years without any adverse effect. CONCLUSION: These results confirm that multiple rTMS sessions are both safe and have potential as a treatment for CNP. An ongoing randomized controlled trial will allow teasing out of this effect from placebo analgesia.
OBJECTIVES: To confirm and extend previous results involving repetitive transcranial magnetic stimulation (rTMS) aimed at alleviating refractory central neuropathic pain (CNP). To evaluate pain relief in detail and to assess ongoing benefits after one year of treatment. DESIGN: Prospective observational study. SETTING: University hospital. Outpatient settings. PARTICIPANTS: Patients (N=80) with chronic central pain after brain or spinal cord injuries. INTERVENTIONS: High-frequency (20Hz) neuronavigated-rTMS sessions were applied on the primary motor cortex using a figure-of-eight coil positioned by a robotized arm. Patients received a minimum of 4 consecutive sessions, each separated by 3-4 weeks. MAIN OUTCOME MEASURES: Percentage of pain relief (%R), duration of pain relief (DPR), numeric rating scale (NRS), neuropathic pain symptom inventory (NPSI), and pain relief score (PRS). RESULTS: Seventy-one patients completed the study. On average, after the first 4 sessions, %R was 28% and DPR was 11 days. Fifty-four patients (76%) were responders with a permissive threshold of ≥10%R and 61% (43 patients) with a stringent threshold ≥30%R. After 12 months of treatment (15 sessions) we observed a cumulative effect on %R (48%), DPR (20d), and on the prevailing NPSI sub-score (-28%). This effect reached significance after 4 sessions and was further maintained over 12 months. Across participants, more than 1000 rTMS sessions were delivered over 6 years without any adverse effect. CONCLUSION: These results confirm that multiple rTMS sessions are both safe and have potential as a treatment for CNP. An ongoing randomized controlled trial will allow teasing out of this effect from placebo analgesia.
Authors: Simone Rossi; Andrea Antal; Sven Bestmann; Marom Bikson; Carmen Brewer; Jürgen Brockmöller; Linda L Carpenter; Massimo Cincotta; Robert Chen; Jeff D Daskalakis; Vincenzo Di Lazzaro; Michael D Fox; Mark S George; Donald Gilbert; Vasilios K Kimiskidis; Giacomo Koch; Risto J Ilmoniemi; Jean Pascal Lefaucheur; Letizia Leocani; Sarah H Lisanby; Carlo Miniussi; Frank Padberg; Alvaro Pascual-Leone; Walter Paulus; Angel V Peterchev; Angelo Quartarone; Alexander Rotenberg; John Rothwell; Paolo M Rossini; Emiliano Santarnecchi; Mouhsin M Shafi; Hartwig R Siebner; Yoshikatzu Ugawa; Eric M Wassermann; Abraham Zangen; Ulf Ziemann; Mark Hallett Journal: Clin Neurophysiol Date: 2020-10-24 Impact factor: 4.861